Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for Ralph Lundberg�
58.68
-0.88 (-1.48%)
After Hours: 58.68 0.00 (0.00%)
Apr 24, 6:28PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 57.35 - 59.18
52 week 47.53 - 61.15
Open 58.31
Vol / Avg. 7.85M/5.03M
Mkt cap 65.71B
P/E 13.60
Div/yield 0.49/3.34
EPS 4.31
Shares 1.12B
Beta 0.34
Inst. own 76%
May 7, 2014
Eli Lilly at EBD Group ChinaBio Partnering Forum - 11:30PM EDT - Add to calendar
May 5, 2014
Eli Lilly Annual Shareholder Meeting (Estimated) Add to calendar
Apr 24, 2014
Q1 2014 Eli Lilly Earnings Release
Apr 24, 2014
Q1 2014 Eli Lilly Earnings Conference Call
Apr 22, 2014
Eli Lilly Conference Call to discuss Acquisition of Novartis Animal Health
Mar 12, 2014
Eli Lilly at Barclays Healthcare Conference
Mar 4, 2014
Eli Lilly at Cowen Health Care Conference
Feb 12, 2014
Eli Lilly at Leerink Swann Global Healthcare Conference
Jan 30, 2014
Q4 2013 Eli Lilly Earnings Release
Jan 30, 2014
Q4 2013 Eli Lilly Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 12.52% 20.27%
Operating margin 15.51% 23.24%
EBITD margin - 29.76%
Return on average assets 8.43% 13.45%
Return on average equity 16.91% 28.92%
Employees 37,925 -
CDP Score - 86 B

Address

Lilly Corporate Center
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company�s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company�s new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In January 2014, acquired all development rights for a calcitonin gene-related peptide (CGRP) antibody.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 48
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 53
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 59
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 44
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 47
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 46
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 48
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 54
Bio & Compensation  - Reuters